Company: NCEL
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001213900-25-025839
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 6-K
Chunk 4
---
 Agreement, dated March 30, 2025, between NLS Pharmaceutics and the certain purchaser thereto.                            |
| 99.4        |     | Form of Pre-Funded Warrant                                                                                                                      |
| 99.5        |     | Press release titled: “NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement.” |

<div align='center'>3

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: March 31, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:---------------------|:-----------------------|:--------------------|:------------------------|
|                      |                        | Name:               | Alexander Zwyer         |
|                      |                        | Title:              | Chief Executive Officer |

<div align='center'>4</div>